Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Formoterol (20mcg) + Budesonide (0.5mg) Respule
Therapeutic Category
Pulmonary, Respiratory, Asthma
Dosage Form
Respule
Packaging Type
Pack
Packaging
4*5*2.5ml
Price
₹400/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Buditerm F Respule is a combination inhalation therapy designed to provide effective management of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). It contains Formoterol, a long-acting beta-agonist that works by relaxing the muscles in the airways, thus helping to improve airflow to the lungs. The Budesonide component is a corticosteroid that reduces inflammation in the airways, helping to prevent asthma attacks and decrease the severity of symptoms.
This combination therapy helps to control both the symptoms and underlying inflammation associated with asthma and COPD. By using Buditerm F Respule, patients experience improved breathing and reduced frequency of flare-ups. It is designed for maintenance therapy and should be used regularly to achieve optimal results.
Buditerm F Respule is intended for use with a nebulizer, which converts the liquid medication into a fine mist that can be inhaled directly into the lungs. This ensures rapid relief and effective treatment of respiratory symptoms.
Common side effects may include throat irritation, cough, headache, or a mild increase in heart rate. Rarely, it may cause hoarseness or fungal infections in the mouth or throat.
Buditerm F Respule is indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) to improve lung function and reduce inflammation.
Not intended for acute asthma attacks. Always follow the prescribed dosage. Consult a healthcare provider if side effects persist.
Store at room temperature, away from heat and direct sunlight. Do not freeze. Keep out of the reach of children.
Composition : Budesonide (0.5mg) Respule
Composition : Budesonide (200mcg) + Formoterol (6mcg) Rota Capsule
Composition : Formoterol (6mcg) + Budesonide (200mcg) Inhaler
Composition : Formoterol 6mcg + Budesonide 400mcg Rota Capsule
Composition : Formoterol (6mcg) + Budesonide (400mcg) Inhaler
Composition : Levosalbutamol (1.25mg) + Budesonide (0.5mg) Respule
Composition : Fluticasone Furoate (27.5mcg) + Azelastine (140mcg)
Composition : Fluticasone Propionate 250mcg + Formoterol Fumarate 6mcg Life Cap
Composition : Fluticasone Furoate (27.5mcg)
Composition : Fluticasone Propionate (0.005% w/v)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Budesonide + Formoterol Respules is a combination nebulization therapy used for the management of asthma, Chronic Obstructive Pulmonary Disease (COPD), wheezing, and other obstructive airway disorders. Budesonide is an inhaled corticosteroid (ICS) that reduces airway inflammation. Formoterol is a long-acting beta-2 agonist (LABA) that relaxes airway muscles and improves airflow. This combination helps improve breathing, reduce respiratory symptoms, and prevent exacerbations, making it a key product in the respiratory and pulmonology segment.
Medical distributors and wholesalers can benefit from strong demand from pulmonologists, pediatricians, hospitals, and emergency care centers. Nebulization therapy is widely used in both acute and chronic respiratory conditions, ensuring consistent prescriptions and repeat demand.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in respiratory, pulmonology, and inhalation therapy segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from high prevalence of asthma and COPD, increasing use of nebulization therapy, and strong specialist-driven prescriptions, making it a stable, high-value, and repeat-order pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in respiratory and nebulization products can contact Cafoli Lifecare to discuss product availability, pricing structure, and PCD pharma franchise opportunities in the pulmonology and respiratory care segment.